Dr. Robby Newman is Principal Scientist of Target Biology at Ankyra Therapeutics, where he leads efforts to identify and validate new targets, optimize lead candidates, and guide programs through IND-enabling studies. With a background spanning pharmacology and immunology, he works across disciplines to turn bold scientific ideas into therapeutic realities.
A preclinical immunologist with over 11 years of postgraduate experience, Dr. Newman has advanced both biologics and small molecule programs from early concepts to therapies poised for clinical evaluation. He is passionate about designing and interpreting pivotal in vitro and in vivo studies that uncover new ways to harness the immune system against disease.
Before joining Ankyra, Dr. Newman was a Principal Scientist at Mural Oncology and held roles of increasing responsibility at Alkermes and Altor Bioscience (acquired by ImmunityBio), where he contributed to the development of ANKTIVA®, an IL‑15 superagonist now approved for the treatment of BCG‑unresponsive non‑muscle invasive bladder cancer. He earned his Ph.D. in Cancer Biology from the University of Miami and his B.S. in Biochemistry from the University of Florida.